HUNGARY BECOMES THE FIRST COUNTRY IN EU TO AUTHORIZE THE SPUTNIK V VACCINE
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“Hungary is the first EU country to realize all the advantages of Sputnik V vaccine and authorize its use. This decision is very important as it demonstrates that the vaccine's safety and efficacy of over 90% are highly regarded by our partners in Hungary.”
Sputnik V has a number of key advantages:
· Efficacy of Sputnik V is over 90%, with full protection against severe cases of COVID-19.
· The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
· Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
· The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
· Over 1.5mn people have already been vaccinated with Sputnik V.
· The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.
· The Sputnik V vaccine has been approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay and Turkmenistan; the process to approve the vaccine in the EU has been initiated.
· There are no strong allergies caused by Sputnik V.
· The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
· The price of Sputnik V is less than $10 per shot, making it affordable around the world.
More information: https://sputnikvaccine.com/newsroom/pressreleases/hungary-becomes-the-first-country-in-eu-to-authorize-the-sputnik-v-vaccine-/
“Hungary is the first EU country to realize all the advantages of Sputnik V vaccine and authorize its use. This decision is very important as it demonstrates that the vaccine's safety and efficacy of over 90% are highly regarded by our partners in Hungary.”
Sputnik V has a number of key advantages:
· Efficacy of Sputnik V is over 90%, with full protection against severe cases of COVID-19.
· The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
· Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
· The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
· Over 1.5mn people have already been vaccinated with Sputnik V.
· The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.
· The Sputnik V vaccine has been approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria, Palestine, Venezuela, Paraguay and Turkmenistan; the process to approve the vaccine in the EU has been initiated.
· There are no strong allergies caused by Sputnik V.
· The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
· The price of Sputnik V is less than $10 per shot, making it affordable around the world.
More information: https://sputnikvaccine.com/newsroom/pressreleases/hungary-becomes-the-first-country-in-eu-to-authorize-the-sputnik-v-vaccine-/